SCOTUS GRANTS REVIEW OF AMGEN V SANDOZ

The Supreme Court of the United States on Friday, January 13, 2017  granted a review of the Amgen v. Sandoz patent dispute case in regards to the FDA licensing of “biologics” (which are products such as viruses, vaccines as well as antitoxins).